{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreiczmy56fbq7tkqoc4bwb4sfdnq4nvmabjk5tggelfrx7nvah3mfye",
    "uri": "at://did:plc:svcthvzunxmjidtlw23zva6n/app.bsky.feed.post/3mn55giinegf2"
  },
  "coverImage": {
    "$type": "blob",
    "ref": {
      "$link": "bafkreibnbbiprl7qbpevztwmor5xrdayfe6ijfw6mlwgl3sagye5anfoby"
    },
    "mimeType": "image/jpeg",
    "size": 12221
  },
  "path": "/2026/05/31/sacituzumab-tirumotecan-sac-tmt-in-combination-with-pembrolizumab-for-first-line-treatment-of-pd-l1-positive-nsclc-published-in-the-lancet/",
  "publishedAt": "2026-05-31T00:00:00.000Z",
  "site": "https://laotiantimes.com",
  "tags": [
    "Cision PR Newswire"
  ],
  "textContent": "CHENGDU, China, May 31, 2026 /PRNewswire/ — Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the “Company”, 6990.HK) announced today that the results of the Phase III clinical study OptiTROP-Lung05, evaluating the company’s trophoblast cell-surface antigen 2 (TROP2)-directed antibody drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT, also known as SKB264/MK-2870)(佳泰莱®) in combination with pembrolizumab (KEYTRUDA®[1], MSD’s anti-programmed cell death protein […]",
  "title": "Sacituzumab Tirumotecan (sac-TMT) in Combination with Pembrolizumab for First-Line Treatment of PD-L1-Positive NSCLC Published in The Lancet"
}